Loading
A phase 1/2 trial of TUB-040 run by Gilead Sciences, not yet recruiting.
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy is a phase 1/2 interventional study registered as NCT07743541 by Gilead Sciences, with 100 participants planned, started 2026-10. Conditions recorded: Uterine Endometrial Cancer. Interventions recorded: TUB-040 - Dose escalation and TUB-040 - RP2D.
Shares TUB-040, Tubulis (Gilead) and the tag pipeline.
Shares TUB-040, Tubulis (Gilead) and the tag pipeline.
Shares Tubulis (Gilead) and the tag pipeline.
Shares Tubulis (Gilead) and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares TUB-040, Tubulis (Gilead).
Shares Endometrial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/